Subscribe
shutterstock_85914670_nagy_bagoly_arpad
Nagy Bagoly Arpad / Shutterstock.com
13 May 2019Big Pharma

44 states accuse big pharma of price fixing generics market

44 US states have filed a joint complaint against 20 drug companies, alleging they engaged in illegal conspiracies to “manipulate prices, reduce competition” and restrain trade for more than 100 generic drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sun Pharma to pay $205m over generics price-fixing
24 July 2020   A subsidiary of India’s Sun Pharma has agreed to pay more than $200 million to settle charges related to a generics price-fixing investigation.
Generics
Teva and FTC reach settlement over ‘pay-for-delay’
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Sun Pharma to pay $205m over generics price-fixing
24 July 2020   A subsidiary of India’s Sun Pharma has agreed to pay more than $200 million to settle charges related to a generics price-fixing investigation.
Generics
Teva and FTC reach settlement over ‘pay-for-delay’
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.

More on this story

Americas
Sun Pharma to pay $205m over generics price-fixing
24 July 2020   A subsidiary of India’s Sun Pharma has agreed to pay more than $200 million to settle charges related to a generics price-fixing investigation.
Generics
Teva and FTC reach settlement over ‘pay-for-delay’
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB